1	Low-attenuation Coronary Plaque Volume and Cardiovascular Events in Patients with
2	Distinct Metabolic Phenotypes
3	
4	Kenichiro Otsuka, MD, PhD1*; Hirotoshi Ishikawa, MD, PhD2; Kenei Shimada, MD, PhD2;
5	Kana Hojo, MD <sup>2</sup> ; Hiroki Yamaura, MD <sup>2</sup> ; Yasushi Kono, MD, PhD <sup>2</sup> ; Noriaki Kasayuki, MD,
6	PhD <sup>2</sup> ; Daiju Fukuda, MD, PhD <sup>1</sup>
7	
8	Affiliations:
9	<sup>1</sup> Department of Cardiovascular Medicine, Osaka Metropolitan University Graduate School of
10	Medicine, Osaka, Japan
11	<sup>2</sup> Department of Cardiovascular Medicine, Fujiikai Kashibaseiki Hospital, Kashiba, Japan
12	
13	Short title: High-risk plaque and patient prognosis
14	
15	*Corresponding author: Kenichiro Otsuka
16	Department of Cardiovascular Medicine
17	Osaka Metropolitan University Graduate School of Medicine
18	1-4-3 Asahi-cho, Abeno-ku, Osaka 545-8585, Japan
19	Tel.: +81-666453801
20	Fax: +81-6646-6808
21	Email: <u>otsukakenichiro1@gmail.com</u>
22	
23	Word count: 6,193 words, including text, figure legends, and reference

#### 24 Abstract

Background: This study aimed to investigate the association between diabetes mellitus (DM),
high-risk coronary plaque burden, and risk of cardiovascular outcomes across metabolic
phenotypes in patients with suspected coronary artery disease (CAD) who underwent coronary
computed tomography angiography (CCTA).

Methods: We included 530 patients who underwent CCTA. Metabolic syndrome (MetS) was defined as the presence of a visceral adipose tissue area  $\geq 100 \text{ cm}^2$  in patients with DM (n = 58), or two or more MetS components excluding DM (n = 114). Remaining patients were categorized into non-MetS patients with DM (n = 52) and non-MetS patients without DM (n = 306). CCTAbased high-risk plaque was defined as low-attenuation plaque (LAP) volume > 4 %. Primary endpoint was presence of a major cardiovascular event (MACE), which was defined as a composite of cardiovascular death, acute coronary syndrome, and coronary revascularization.

36 **Results**: Incidence of MACE was highest in the non-MetS with DM group, followed 37 hierarchically by the MetS with DM, MetS without DM, and non-MetS without DM groups. In 38 the multivariable Cox hazard model analysis, DM as a predictor was associated with MACE 39 independent of LAP volume > 4 % (hazard ratio, 2.68; 95% confidence interval, 1.16–6.18; p = 40 0.02), although MetS did not remain an independent predictor. LAP volume > 4 % remained a 41 predictor of MACE independent of each metabolic phenotype or DM.

42 Conclusions: This study demonstrated that DM, rather than MetS, is a predictor of coronary
43 events independent of high-risk plaque volume in patients who underwent CCTA.

44

45 Keywords

46 acute coronary syndrome, adipose tissue, computed tomography angiography, coronary artery
47 disease, diabetes mellitus

48

#### 49 Clinical Perspective

50 1) What Is New?

This study investigated the association between diabetes mellitus (DM), high-risk coronary
 plaque burden, and major adverse cardiovascular events (MACE) across metabolic
 phenotypes stratified by the presence or absence of metabolic syndrome (MetS) and DM in
 patients with suspected coronary artery disease (CAD) who underwent coronary computed
 tomography angiography (CCTA).

Among the four metabolic phenotypes, incidence of MACE was highest in the non-MetS with DM group, followed hierarchically by the MetS with DM, MetS without DM, and non-MetS without DM groups. Low-attenuation coronary plaque (LAP) volume > 4% was a robust predictor of MACE among the metabolic phenotypes. Furthermore, DM, independent of LAP volume > 4%, was a predictor of MACE, while MetS did not show a significant predictive value.

62 2) What Are the Clinical Implications?

Our results demonstrate that individuals with DM alone have a significantly higher risk of
 developing cardiovascular events than those with MetS, indicating that DM is an
 independent predictor of cardiovascular events irrespective of the presence of obstructive
 CAD or LAP volume greater than 4%.

67

#### 68 Non-standard Abbreviations and Acronyms.

- 69 ACS- acute coronary syndrome
- 70 ASCVD- Atherosclerotic cardiovascular disease
- 71 CACS- Coronary artery calcium score
- 72 CAD- coronary artery disease
- 73 CCTA- coronary computed tomography angiography
- 74 CP- Calcified plaques
- 75 DM- diabetes mellitus
- 76 LAP- Low-attenuation plaque
- 77 MACE- Major adverse cardiovascular events
- 78 MetS- Metabolic Syndrome
- 79 NCP- noncalcified plaque
- 80

#### 81 Introduction

82 The global prevalence of diabetes mellitus (DM) and metabolic syndrome (MetS) has 83 increased significantly over the past decades, contributing to an increased risk of atherosclerotic cardiovascular disease (ASCVD)<sup>1</sup>. Clinical studies have demonstrated that an overweight status 84  $(25-29.9 \text{ kg/m}^2)$  or obesity ( $\geq 30 \text{ kg/m}^2$ ), defined by body mass index (BMI) alone, reflects 85 86 heterogeneous body fat distribution and distinct metabolic conditions<sup>2</sup>. This raises questions 87 about the relationship between BMI and ASCVD risk, which leads to the obesity paradox. Although visceral adiposity, a modifiable risk factor for MetS, helps identify metabolically 88 89 unhealthy individuals <sup>1-4</sup>, coronary plaque features associated with ASCVD events in individuals 90 with distinct metabolic phenotypes remain largely unknown.

91 Coronary computed tomography angiography (CCTA) facilitates the diagnosis of 92 coronary artery disease (CAD) and offers a prognostic value based on high-risk coronary plaque features beyond stenosis severity <sup>5</sup>. Furthermore, a recent CCTA study demonstrated that low-93 94 attenuation non-calcified coronary plaque burden is the strongest prognostic marker among other clinical factors, such as the presence of CAD and coronary artery calcium score (CACS)<sup>6</sup>. This 95 96 finding suggests the utility of CCTA in identifying high-risk patients. In a sub-analysis of a large 97 clinical CCTA trial of patients with chest pain and distinct metabolic phenotypes, Kammerlander 98 et al. demonstrated that metabolically unhealthy individuals without obesity were at a high risk for ASCVD events<sup>7</sup>. Although DM plays a key role in the pathophysiology of MetS<sup>8</sup>, there is 99 100 limited knowledge on its association with high-risk plaque volume detected on CCTA and 101 consequent cardiovascular outcomes. In this CCTA study, we aimed to investigate the 102 association between MetS with and without DM, imaging findings, and the risk of outcomes 103 across MetS phenotypes.

104

#### 105 Methods

106 The data that support the findings of this study are available from the corresponding author on107 reasonable request.

108

#### 109 Study population and metabolic phenotypes

This study included patients who underwent CCTA between January 2018 and December 2020 and were clinically indicated for stable chest symptoms, along with an abdominal computed tomography (CT) scan to assess abdominal obesity. The exclusion criteria were as follows: (1) acute coronary syndrome; (2) previous history of coronary artery bypass graft or open-heart surgery; (3) congestive heart failure; (4) previous history of percutaneous coronary intervention; (5) insufficient patient information; and (6) loss to follow-up. Figure 1 illustrates the flowchart of the study population comprising 530 patients. All participants provided written informed consent for the use of de-identified data, including clinical information, laboratory tests, and CCTA imaging. The Fujiikai Kashibaseiki Hospital Institutional Review Board approved pooled data analysis (2021-A).

120 Non-contrast-enhanced abdominal CT imaging was performed before CCTA to measure 121 the visceral adipose tissue (VAT) areas. VAT areas were measured at the L2-L3 level using a 122 dedicated software (SYNAPSE VINCENT, Fujifilm Inc., Tokyo, Japan). In the present study, abdominal obesity was defined as a VAT area  $\geq 100 \text{ cm}^2$ , corresponding to an abdominal 123 circumference  $\ge 85$  cm for men and  $\ge 90$  cm for women <sup>9</sup>. MetS was defined based on the 124 Japanese Committee for the Diagnostic Criteria of Metabolic Syndrome<sup>10</sup>. MetS was defined as 125 126 the presence of abdominal obesity with DM (MetS with DM) or two or more of the following 127 components in the absence of DM: (1) systolic blood pressure (BP)  $\geq$ 130 mmHg or diastolic BP 128  $\geq$ 85 mmHg; (2) fasting plasma glucose  $\geq$ 110 mg/dL; and (3) triglycerides  $\geq$ 150 mg/dL or high-129 density lipoprotein cholesterol  $\leq 40 \text{ mg/dL}$ . In addition, medical therapy using antihypertensive, 130 antidiabetic, and lipid-lowering drugs was considered an MetS component. Patients were further 131 categorized into four groups according to the presence or absence of metabolic equivalents 132 (MetS) and DM. The triglyceride-glucose (TyG) index was used to estimate the insulin resistance in the four groups <sup>11</sup>. 133

Pharmacological treatment and lifestyle modifications were recommended for all patients according to the guidelines for hypertension, dyslipidemia, and diabetes, if present <sup>12</sup>. In addition, patients underwent invasive coronary angiography or coronary revascularization based on the

results of the CCTA and noninvasive stress tests <sup>13</sup>. According to the Japanese Atherothrombosis 137 138 Society guidelines, the treatment targets of low-density lipoprotein cholesterol (LDL-C) for the 139 primary prevention of ASCVD were <100 mg/dL for high-risk, 120 mg/dL for moderate-risk, or 140 mg/dL for low-risk patients <sup>12</sup>. The treatment target for the fasting triglyceride (TG) level 140 141 was < 150 mg/dL. For hypertensive patients, the treatment target for blood pressure is < 140/90mmHg, particularly for patients with diabetes or CKD with albuminuria <130/80 mmHg<sup>14</sup>. The 142 143 target glycemic control was HbA1c < 7.0% for preventing diabetic complications and < 8.0% for those with difficulties in glycemic control for hypoglycemia<sup>15</sup>. 144

145

# 146 CCTA imaging and analysis

147 CCTA was performed using a 320-row multi-detector CT scanner (Aquilion ONE/NATURE Edition, Canon Medical Systems, Inc., Japan)<sup>16</sup>. The scan parameters included a 148 149 detector collimation of  $0.5 \times 320$  mm, gantry rotation time of 350 ms, tube voltage of 120 kV, 150 and tube current of 130-600 mA. An electrocardiogram-triggered prospective gating method was used for CCTA. CACS was evaluated using the Agatston method at a fixed thickness of 3 mm<sup>17</sup>. 151 152 Images were reconstructed using forward projected model-based iterative reconstruction solution 153 for coronary artery analysis, with a cross-sectional thickness of 0.5 mm and a reconstruction 154 increment of 0.25 mm.

The Agatston score categories were as follows: 0, 1–100, 101–400, and >400 Agatston units, using a software (SYNAPSE VINCENT version 4.6., Fujifilm inc., Tokyo, Japan). Coronary artery diameter stenosis was reported based on a 16-segment American Heart Association model by two observers (K.O. and H.I.). Obstructive CAD was defined as the presence of coronary plaques with diameter stenosis of  $\geq$  50% in one or more major epicardial

160 vessels, and/or  $\ge 50\%$  in the left main coronary segment. Non-obstructive CAD was defined as 161 having less than 50% diameter stenosis of epicardial coronary arteries. Patients who did not fall 162 in either categories were categorized as not having CAD.

For coronary plaque analysis, coronary artery centerlines were identified semiautomatically; the proximal and distal portions of the coronary plaque lesions were manually defined; and the vessel wall, lumen, and plaque components were auto-segmented and manually adjusted. Lesions were categorized based on their composition into calcified plaques (CP) (> 150 Hounsfield units [HU]) and non-CP (NCP) (< 150 HU). Furthermore, a low-attenuation plaque (LAP) was defined as a region with a CT value < 30 HU <sup>16</sup>. The percentage of plaque volume for each component was calculated as the plaque volume divided by the vessel volume.

170 The epicardial adipose tissue (EAT) volume was measured from contrast-enhanced CT images using the VINCENT software, cited previously <sup>16,18</sup>. Several equidistant axial planes 171 172 were extracted based on the heart size. The upper limit of the slice was set at the bifurcation of 173 the pulmonary artery trunk, whereas the lower limit was set at the last slice containing any 174 structure of the heart. In each plane, the software autodetected a smooth, closed pericardial 175 contour as the region of interest; adipose tissue was identified with CT attenuation values 176 ranging from -250 to -30 HU within the pericardial sac <sup>16,18</sup>. Finally, EAT volume was calculated 177 as the sum of the EAT areas in each slice. The mean CT value within the measured EAT volume 178 was reported.

179

# 180 Endpoints

181 The primary endpoint was major adverse cardiovascular events (MACE) defined by a 182 composite of cardiovascular death, nonfatal myocardial infarction, unstable angina, or symptom-

183 or ischemia-driven coronary revascularization. Cardiovascular death was defined as death due to 184 cardiovascular causes including myocardial infarction, sudden cardiac arrest, heart failure, and stroke <sup>19</sup>. Non-fatal myocardial infarction was defined as typical persistent chest pain with 185 elevated cardiac enzymes <sup>19</sup>. Unstable angina was defined as new-onset angina, exacerbation of 186 187 angina with light exertion, or angina at rest without elevated cardiac enzyme levels. Symptom- or 188 ischemia-driven coronary revascularization was defined as coronary revascularization >3 months 189 after CCTA imaging at baseline, with >75% diameter stenosis with symptoms, or positive 190 functional tests, or with a  $\geq 90\%$  diameter stenosis with symptoms.

191

## 192 Statistical analysis

193 All statistical analyses were performed using SPSS version 24 software (IBM Corp., 194 Armonk, NY, USA). Categorical variables were presented as absolute and relative frequencies, 195 and continuous variables were presented as mean (±standard deviation). Subject characteristics 196 were compared using one-way analysis of variance for numerical variables. Categorical variables 197 were analyzed using the chi-square or Fisher's exact tests. Multivariate Cox proportional hazards 198 analysis was used to estimate hazard ratios (HRs) with 95% confidence intervals (CIs). To test 199 the hypothesis that DM or MetS serve as a predictor of MACE independent of high-risk plaque 200 volume, DM (or MetS) and LAP volume > 4% were entered into the multivariate Cox 201 proportional hazards models adjusted for the Suita CVD risk score (model 1 and model 2). 202 Furthermore, to test the hypothesis that each metabolic phenotype remains as a predictor of 203 MACE independent of high-risk plaque volume, each metabolic phenotype, as compared with 204 non-DM without MetS and LAP volume > 4%, were entered into the multivariate Cox 205 proportional hazards models adjusted for the Suita CVD risk score (models 3, 4, and 5).

Additionally, multivariable models were constructed. Variables entered into the multivariate models were selected on the basis of clinical plausibility, multicollinearity, and known association with CV death and acute coronary syndrome (ACS), with the adjustment for Suita CVD risk score: Model 1, LAP volume > 4% and TyG index; Model 2, LAP volume > 4% and CKD; Model 3, LAP volume > 4% and CRP; and Model 4, LAP volume > 4% and obstructive CAD (any vessels) (supplementary Table 1).

Kaplan–Meier curves and log-rank tests were used to depict and assess the differences in cumulative event rates among the four groups. Analyses were initiated at the time of CCTA imaging and terminated at the earliest occurrence of the primary endpoint or at the median follow-up (2.91 years). Analyses were censored at the last follow-up or at a composite event, whichever occurred earlier. Statistical significance was set at p < 0.05 (two-sided).

217

#### 218 Results

All CCTA images of the 530 patients qualified for analysis. The mean age of the patients was  $64 \pm 14$  years, and 299 (56%) patients were men. Baseline characteristics stratified by metabolic phenotype are presented in Table 1. MetS were present in 172 of the 530 patients (32%), and DM was observed in 110 (21%). Of these, DM was present in 52 patients in the non-MetS (15%) and 58 in the MetS group (44%). The highest TyG index was observed in the patients with metabolic equivalents (MetS) and DM, followed by those without DM, non-MetS with DM, and non-MetS without DM.

Table 2 shows the baseline CCTA findings of the four groups. The prevalence of CACS > 400 was greatest in the MetS with DM (22%) and non-MetS with DM groups (21%, overall p < 0.001). The frequency of obstructive CAD was the highest in the non-MetS with DM group

229 (58%), sequentially followed by the MetS with DM (46%), MetS without DM (39%), and non-230 MetS without DM groups (36%). The MetS with DM group featured greater NCP, LAP, and CP 231 volumes than those without DM. While significantly greater EAT volumes were observed in 232 individuals with MetS than in those without MetS, there was no significant difference in DM. 233 Non-MetS with DM had the lowest mean CT values among the four groups (p < 0.001).

234

# 235 **Primary outcome**

During a mean follow-up period of  $2.7 \pm 0.9$  years (median 2.91 years), MACE was observed in 25 patients (4.7%). The primary outcome was observed in seven patients in the non-MetS without DM group, eight in the non-MetS with DM group, six in the MetS without DM group, and four in the MetS with DM group. The incidence rate for the composite endpoint was highest in the non-MetS with DM group, followed hierarchically by the MetS with DM, MetS without DM, and non-MetS without DM group (p < 0.001, log-rank test; Figure 2).

242 Table 3 summarizes the unadjusted Cox proportional hazards models used to predict the 243 primary endpoint. CACS > 400 (p < 0.001), LAP volume > 4% (p < 0.001), obstructive CAD 244 (patient-level and vessel-level, p < 0.05), and DM (p < 0.001) were significantly associated with 245 the primary endpoint. Patients with angiographically confirmed MACE (n = 20) exhibited 246 significantly higher prevalence of LAP volume > 4% in LAD (45% versus 23.5%; p = 0.036) 247 and RCA (40% versus 18%; p = 0.035) and tended to have higher prevalence of LAP volume > 248 4% in LCX (20% vs. 9.3%; p = 0.09) compared to those without MACE. In the multivariable 249 Cox proportional hazards model analysis (Table 4), DM as a predictor was associated with the 250 primary endpoint, independent of LAP volume > 4% (HR for DM in model 1; HR, 2.68; 95% CI, 251 1.16-6.18; p = 0.02), although MetS did not remain an independent predictor (model 2 in Table

252	4). For the subgroup analysis of each metabolic phenotype (non-DM without MetS as reference),
253	DM without MetS remained as a predictor of MACE independent of LAP volume > 4% (model
254	3), whereas DM with MetS (model 4) or non-DM with MetS (model 5) did not reach statistical
255	significance. Finally, we examined the association of MACEs with parameters other than DM or
256	MetS. In the multivariable models, TyG index (HR, 1.78; 95% CI, 1.10–2.89; $p = 0.019$ ) or
257	obstructive CAD (HR, 5.49; 95% CI, 1.84–16.38; $p = 0.002$ ) was independently associated with
258	MACE even after adjusting for the Suita CVD risk score, but CKD or CRP did not remain as a
259	predictor (supplementary Table 1).

260

# 261 Discussion

This study investigated the association between distinct metabolic phenotypes according to the presence or absence of MetS and DM, and cardiovascular outcomes in symptomatic patients undergoing CCTA. The major findings of this study were as follows: (1) among the four groups, the worst prognosis was observed in non-MetS patients with DM compared to MetS patients with or without DM; (2) LAP volume > 4% was a robust predictor of MACE among the metabolic phenotypes; and (3) DM, independent of LAP volume > 4%, was a predictor of the primary endpoint; while MetS did not show a significant predictive value.

269

# 270 Metabolic disorders, high-risk plaque burden, and outcomes

271 Several large clinical trials have demonstrated that myocardial ischemia is an important 272 surrogate marker for improving outcomes in patients with stable CAD, whereas ischemia-guided 273 management has a limited ability to prevent acute coronary events compared with optimized 274 medical therapy <sup>20,21</sup>. These findings question the credibility of ischemia-guided management of

patients with stable CAD, thus redirecting attention towards coronary microvascular dysfunction and high-risk plaque burden <sup>22–24</sup>. An increased plaque burden, especially of non-calcified plaques, has been reported in patients with MetS <sup>25</sup>. Yonetsu et al. used optical coherence tomography to demonstrate that MetS were associated with an increased burden of lipid-rich plaques <sup>25</sup>. Although these findings indicate a potential link between obesity, metabolic disorders, and unfavorable coronary plaque features, there is limited knowledge regarding coronary plaque burden in distinct metabolic phenotypes with and without DM.

282 Previous clinical studies have reported an inverse association between BMI and cardiovascular prognosis (obesity paradox)<sup>7,26,27</sup>. In patients with ASCVD and DM, Pagidipati et 283 284 al. demonstrated that overweight or obese individuals had a lower cardiovascular risk than those 285 with normal weight <sup>27</sup>. In a sub-analysis of a large clinical CCTA trial of patients with chest pain, 286 among distinct metabolic phenotypes, Kammerlander et al. demonstrated that metabolically 287 unhealthy individuals without obesity exhibited an increased high-risk plaque burden and a high risk of ASCVD events <sup>7</sup>. This paradoxically benign effect of obesity may be explained by its 288 289 protective effect against atherosclerosis. Obese patients lack sarcopenia, have limited capacity 290 for exercise, and have reduced mobility, all of which are associated with an increased incidence of cognitive decline, heart failure, and mortality <sup>28</sup>. In addition, we observed increased fasting 291 292 plasma glucose levels in patients with non-MetS DM. Hyperglycemia and insulin resistance have been reported to be key drivers of calcification in DM<sup>8,11,29</sup>. Liu et al. showed that higher 293 294 glucose levels and their variability are associated with plaque rupture in patients with STsegment elevation myocardial infarction <sup>30</sup>. These findings suggest that metabolic phenotypes 295 296 can help identify patients at high risk of cardiovascular events in addition to a high-risk plaque 297 burden.

298

#### 299 Epicardial adipose tissue, plaque characteristics, and outcomes

CAD is a chronic inflammatory disease with an underlying risk of metabolic disorders <sup>31</sup>. 300 301 A close relationship between abdominal visceral obesity and an increased coronary atherosclerotic burden has been reported <sup>4,32</sup>. Our results demonstrated that MetS patients with or 302 303 without DM had increased EAT and LAP volumes, whereas non-MetS patients with DM had the 304 worst outcomes, with lower EAT and LAP volumes, indicating an alternate pathophysiology of 305 acute coronary syndromes in the latter. Our findings are consistent with the observations of 306 Kammerlander et al., who demonstrated that both metabolically unhealthy obese and non-obese subjects exhibited increased high-risk plaques <sup>7</sup>. The increased prevalence of obstructive CAD 307 308 and vascular calcification (CP) in patients with DM offers a possible explanation for this finding 309 <sup>33</sup>. Distinct plaque characteristics may reflect different (advanced or less advanced) stages of 310 coronary atherosclerosis, resulting in different responses to lipid-lowering therapy <sup>34</sup>. 311 Furthermore, previous studies investigating plaque structural stress have demonstrated that 312 microcalcifications contribute to increased stress, leading to plaque rupture and myocardial infarction <sup>35,36</sup>. These observations explain the poor outcomes of patients with DM without MetS 313 314 in this study.

Although we found that the EAT volume was not correlated with outcomes, the mean CT value of the EAT was associated with cardiovascular outcomes (Table 3). EAT has been associated with coronary atherosclerosis, calcification, and cardiovascular outcomes, and has attracted attention as a therapeutic target <sup>18,37–40</sup>. This has motivated the development of imaging methods that enable the assessment of inflammation in the pericoronary adipose tissue, which interacts with the underlying vascular wall by producing proinflammatory adipokines <sup>41</sup>. In a

321 retrospective CCTA study, Oikonomou et al. demonstrated that a fat attenuation index > -70 HU 322 around the epicardial coronary arteries predicts cardiovascular outcomes  $^{42}$ . Higher CT 323 attenuation of the EAT indicates an increased inflammatory status, which supports our finding 324 that non-MetS patients with DM have the worst prognosis.

325 In addition to plaque burden and metabolic disorders, coronary microvascular 326 dysfunction may explain the association between non-MetS patients with DM and poorer outcomes <sup>43,44</sup>. In a systematic analysis, Kelshiker et al. demonstrated that patients with DM were 327 328 more likely to have impaired coronary microvascular function, which presumably indicates a poor prognosis <sup>44</sup>. Although the assessment of coronary microvascular dysfunction is appreciated, 329 330 routine non-invasive evaluation methods are not available in daily clinical practice. Noninvasive 331 assessment of the coronary plaque burden and metabolic phenotypes allows for further risk 332 stratification of symptomatic patients undergoing CCTA.

333

#### 334 Study limitations

335 This study included a relatively small number of patients, and the event rates during 336 follow-up were relatively low (< 5%). Our findings should be interpreted with caution since the 337 DM with MET group was significantly older than the other groups with more obstructive CAD. 338 Further studies are required to confirm these findings. Furthermore, although a unified definition is needed, the criteria for abdominal obesity vary among races <sup>45</sup>. In the present study, we used 339 340 quantitative VAT values obtained from CT scans to define abdominal obesity. Lastly, we did not 341 perform laboratory tests such as HOMA-IR to measure insulin resistance, which is associated with inflammation <sup>46</sup> and plaque vulnerability <sup>8</sup>. Instead, we calculated the TyG index and 342 343 reported its significant association with the primary endpoint, independent of LAP volume > 4%

344	(HR for TyG index, 1.78; 95% CI, 1.10–2.89; $p = 0.019$ ) (Model 1, in the supplementary Table
345	1).
346	
347	Conclusions
348	Individuals with DM alone have a significantly higher risk of developing MACE than
349	those with MetS. This indicates that DM is an independent predictor of ASCVD events
350	irrespective of the presence of obstructive CAD or high-risk plaque volume.
351	
352	Acknowledgements
353	Not applicable
354	Sources of Funding
355	None
356	Disclosures
357	The authors declare that they have no competing interests.
358	Supplemental Material
359	Supplementary table 1
360	
361	
362	
363	
364	
365	References

1.	Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, Lear SA,
	Ndumele CE, Neeland IJ, Sanders P, St-Onge MP. Obesity and Cardiovascular Disease: A
	Scientific Statement from the American Heart Association. Circulation. 2021;143:E984-
	E1010.
2.	Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity
	benign conditions?: A systematic review and meta-analysis. Ann Intern Med.
	2013;159:758–769.
3.	DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients
	with obesity. Nat Rev Endocrinol. 2014;10:364–376.
4.	Eckel N, Li Y, Kuxhaus O, Stefan N, Hu FB, Schulze MB. Transition from metabolic
	healthy to unhealthy phenotypes and association with cardiovascular disease risk across
	BMI categories in 90 257 women (the Nurses' Health Study): 30 year follow-up from a
	prospective cohort study. Lancet Diabetes Endocrinol. 2018;6:714-724.
5.	Otsuka K, Fukuda S, Tanaka A, Nakanishi K, Taguchi H, Yoshikawa J, Shimada K,
	Yoshiyama M. Napkin-ring sign on coronary CT angiography for the prediction of acute
	coronary syndrome. JACC Cardiovasc Imaging. 2013;6:448-457.
6.	Williams MC, Kwiecinski J, Doris M, McElhinney P, D'Souza MS, Cadet S, Adamson
	PD, Moss AJ, Alam S, Hunter A, Shah ASV, Mills NL, Pawade T, Wang C, Weir McCall
	J, Bonnici-Mallia M, Murrills C, Roditi G, Van Beek EJR, Shaw LJ, Nicol ED, Berman
	DS, Slomka PJ, Newby DE, Dweck MR, Dey D. Low-Attenuation Noncalcified Plaque on
	Coronary Computed Tomography Angiography Predicts Myocardial Infarction: Results
	from the Multicenter SCOT-HEART Trial (Scottish Computed Tomography of the
	HEART). Circulation. 2020;141:1452–1462.
	<ol> <li>1.</li> <li>2.</li> <li>3.</li> <li>4.</li> <li>5.</li> <li>6.</li> </ol>

389	7.	Kammerlander AA, Mayrhofer T, Ferencik M, Pagidipati NJ, Karady J, Ginsburg GS, Lu
390		MT, Bittner DO, Puchner SB, Bihlmeyer NA, Meyersohn NM, Emami H, Shah SH,
391		Douglas PS, Hoffmann U. Association of Metabolic Phenotypes With Coronary Artery
392		Disease and Cardiovascular Events in Patients With Stable Chest Pain. Diabetes Care.
393		2021;44:1038–1045.
394	8.	Iguchi T, Hasegawa T, Otsuka K, Matsumoto K, Yamazaki T, Nishimura S, Nakata S,
395		Ehara S, Kataoka T, Shimada K, Yoshiyama M. Insulin resistance is associated with
396		coronary plaque vulnerability: insight from optical coherence tomography analysis. Eur
397		Hear Journal Cardiovasc Imaging. 2014;15:284–291.
398	9.	New criteria for "obesity disease" in Japan. Circ J. 2002;66:987-992.
399	10.	Matsuzawa Y. Metabolic syndromedefinition and diagnostic criteria in Japan. $J$
400		Atheroscler Thromb. 2005;12:301.
401	11.	Zhao Q, Zhang TY, Cheng YJ, Ma Y, Xu YK, Yang JQ, Zhou YJ. Impacts of triglyceride-
402		glucose index on prognosis of patients with type 2 diabetes mellitus and non-ST-segment
403		elevation acute coronary syndrome: Results from an observational cohort study in China.
404		Cardiovasc Diabetol. 2020;19:1–19.
405	12.	Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G,
406		Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K,
407		Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Biro S, Fujioka Y,
408		Maruyama C, Miyamoto Y, Murakami Y, Yokode M, Yoshida H, Rakugi H, Wakatsuki A,
409		Yamashita S. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of
410		Atherosclerotic Cardiovascular Diseases 2017. J Atheroscler Thromb. 2018;25:846–984.

411	13.	Nakamura M, Yaku H, Ako J, Arai H, Asai T, Chikamori T, Daida H, Doi K, Fukui T, Ito
412		T, Kadota K, Kobayashi J, Komiya T, Kozuma K, Nakagawa Y, Nakao K, Niinami H,
413		Ohno T, Ozaki Y, Sata M, Takanashi S, Takemura H, Ueno T, Yasuda S, Yokoyama H,
414		Fujita T, Kasai T, Kohsaka S, Kubo T, Manabe S, Matsumoto N, Miyagawa S, Mizuno T,
415		Motomura N, Numata S, Nakajima H, Oda H, Otake H, Otsuka F, Sasaki K-I, Shimada K,
416		Shimokawa T, Shinke T, Suzuki T, Takahashi M, Tanaka N, Tsuneyoshi H, Tojo T, Une
417		D, Wakasa S, Yamaguchi K, Akasaka T, Hirayama A, Kimura K, Kimura T, Matsui Y,
418		Miyazaki S, Okamura Y, Ono M, Shiomi H, Tanemoto K. JCS/JSCVS 2018 Guideline on
419		Revascularization of Stable Coronary Artery Disease. Circ J. 2022;86:477-588.
420	14.	Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide S,
421		Ikeda S, Ishimitsu T, Ito M, Ito S, Iwashima Y, Kai H, Kamide K, Kanno Y, Kashihara N,
422		Kawano Y, Kikuchi T, Kitamura K, Kitazono T, Kohara K, Kudo M, Kumagai H,
423		Matsumura K, Matsuura H, Miura K, Mukoyama M, Nakamura S, Ohkubo T, Ohya Y,
424		Okura T, Rakugi H, Saitoh S, Shibata H, Shimosawa T, Suzuki H, Takahashi S, Tamura K,
425		Tomiyama H, Tsuchihashi T, Ueda S, Uehara Y, Urata H, Hirawa N. The Japanese
426		Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).
427		Hypertens Res. 2019;42:1235–1481.
428	15.	Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H, Osawa H, Taguchi A, Tanizawa
429		Y, Tobe K, Yoshioka N. Japanese Clinical Practice Guideline for Diabetes 2019. Diabetol
430		Int. 2020;11:165–223.
431	16.	Yamaura H, Otsuka K, Ishikawa H, Shirasawa K, Fukuda D, Kasayuki N. Determinants of
432		Non-calcified Low-Attenuation Coronary Plaque Burden in Patients Without Known

- 433 Coronary Artery Disease: A Coronary CT Angiography Study. *Front Cardiovasc Med.*434 2022;9:824470.
- 435 17. Hecht HS, Blaha MJ, Kazerooni EA, Cury RC, Budoff M, Leipsic J, Shaw L. CAC-DRS:
- 436 Coronary Artery Calcium Data and Reporting System. An expert consensus document of
- 437 the Society of Cardiovascular Computed Tomography (SCCT). J Cardiovasc Comput
- 438 *Tomogr.* 2018;12:185–191.
- 439 18. Nakanishi K, Fukuda S, Tanaka A, Otsuka K, Jissho S, Taguchi H, Yoshikawa J, Shimada
- 440 K. Persistent epicardial adipose tissue accumulation is associated with coronary plaque
- 441 vulnerability and future acute coronary syndrome in non-obese subjects with coronary
- 442 artery disease. *Atherosclerosis*. 2014;237:353–360.
- 443 19. Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y,
- 444 Morel M-A, van Es G-A, Zuckerman B, Fearon WF, Taggart D, Kappetein A-P, Krucoff
- 445 MW, Vranckx P, Windecker S, Cutlip D, Serruys PW. Standardized End Point Definitions
- 446 for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus
- 447 Document. *Eur Heart J.* 2018;39:2192–2207.
- 448 20. Shaw LJ, Berman DS, Maron DJ, Mancini GBJ, Hayes SW, Hartigan PM, Weintraub WS,
- 449 O'Rourke RA, Dada M, Spertus JA, Chaitman BR, Friedman J, Slomka P, Heller G V.,
- 450 Germano G, Gosselin G, Berger P, Kostuk WJ, Schwartz RG, Knudtson M, Veledar E,
- 451 Bates ER, McCallister B, Teo KK, Boden WE. Optimal medical therapy with or without
- 452 percutaneous coronary intervention to reduce ischemic burden: results from the Clinical
- 453 Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial
- 454 nuclear substudy. *Circulation*. 2008;117:1283–1291.

455	21.	Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman
456		BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman
457		JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava
458		B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB,
459		Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis
460		K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg
461		PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE, Rockhold
462		FW, Broderick S, Ferguson TB, Williams DO, Harrington RA, Stone GW, Rosenberg Y.
463		Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med.
464		2020;382:1395–1407.
465	22.	Otsuka K, Fukuda S, Tanaka A, Nakanishi K, Taguchi H, Yoshiyama M, Shimada K,
466		Yoshikawa J. Prognosis of vulnerable plaque on computed tomographic coronary
467		angiography with normal myocardial perfusion image. Eur Heart J Cardiovasc Imaging.
468		2014;15:332–340.
469	23.	Reynolds HR, Picard MH, Spertus JA, Peteiro J, Lopez Sendon JL, Senior R, El-Hajjar
470		MC, Celutkiene J, Shapiro MD, Pellikka PA, Kunichoff DF, Anthopolos R, Alfakih K,
471		Abdul-Nour K, Khouri M, Bershtein L, De Belder M, Poh KK, Beltrame JF, Min JK, Fleg
472		JL, Li Y, Maron DJ, Hochman JS. Natural History of Patients with Ischemia and No
473		Obstructive Coronary Artery Disease: The CIAO-ISCHEMIA Study. Circulation.
474		2021;144:1008–1023.
475	24.	Newby DE, Williams MC, Dweck MR. Forget Ischemia: It's All about the Plaque.
476		Circulation. 2021;144:1039–1041.

477	25.	Yonetsu T, Kato K, Uemura S, Kim BK, Jang Y, Kang SJ, Park SJ, Lee S, Kim SJ, Jia H,
478		Vergallo R, Abtahian F, Tian J, Hu S, Yeh RW, Sakhuja R, McNulty I, Lee H, Zhang S,
479		Yu B, Kakuta T, Jang IK. Features of coronary plaque in patients with metabolic
480		syndrome and diabetes mellitus assessed by 3-vessel optical coherence tomography. Circ
481		Cardiovasc Imaging. 2013;6:665–673.
482	26.	Costanzo P, Cleland JGF, Pellicori P, Clark AL, Hepburn D, Kilpatrick ES, Perrone-
483		Filardi P, Zhang J, Atkin SL. The obesity paradox in type 2 diabetes mellitus: relationship
484		of body mass index to prognosis: a cohort study. Ann Intern Med. 2015;162:610-618.
485	27.	Pagidipati NJ, Zheng Y, Green JB, McGuire DK, Mentz RJ, Shah S, Aschner P, Delibasi
486		T, Rodbard HW, Westerhout CM, Holman RR, Peterson ED. Association of obesity with
487		cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease:
488		Insights from TECOS. Am Heart J. 2020;219:47–57.
489	28.	Roubenoff R. Sarcopenia and its implications for the elderly. Eur J Clin Nutr. 2000;54
490		Suppl 3:S40-7.
491	29.	Nishimoto S, Fukuda D, Sata M. Emerging roles of Toll-like receptor 9 in cardiometabolic
492		disorders. Inflamm Regen. 2020;40:18.
493	30.	Liu J, Wang S, Cui C, Cai H, Sun R, Pan W, Fang S, Yu B. The association between
494		glucose-related variables and plaque morphology in patients with ST-segment elevated
495		myocardial infarction. Cardiovasc Diabetol. 2020;19:109.
496	31.	Libby P. The changing landscape of atherosclerosis. Nature. 2021;592:524-533.
497	32.	Tanaka T, Kishi S, Ninomiya K, Tomii D, Koseki K, Sato Y, Okuno T, Sato K, Koike H,
498		Yahagi K, Komiyama K, Aoki J, Tanabe K. Impact of abdominal fat distribution, visceral

499	fat, and subcutaneous fat on coronary plaque scores assessed by 320-row computed
500	tomography coronary angiography. Atherosclerosis. 2019;287:155-161.

- 501 33. Jin H-Y, Weir-McCall JR, Leipsic JA, Son J-W, Sellers SL, Shao M, Blanke P, Ahmadi A,
- 502 Hadamitzky M, Kim Y-J, Conte E, Andreini D, Pontone G, Budoff MJ, Gottlieb I, Lee
- 503 BK, Chun EJ, Cademartiri F, Maffei E, Marques H, de Araujo Goncalves P, Shin S, Choi
- 504 JH, Virmani R, Samady H, Stone PH, Berman DS, Narula J, Shaw LJ, Bax JJ, Chinnaiyan
- 505 K, Raff G, Al-Mallah MH, Lin FY, Min JK, Sung JM, Lee S-E, Chang H-J. The
- 506 Relationship Between Coronary Calcification and the Natural History of Coronary Artery
- 507 Disease. JACC Cardiovasc Imaging. 2021;14:233–242.
- Almeida SO, Budoff M. Effect of statins on atherosclerotic plaque. *Trends Cardiovasc Med.* 2019;29:451–455.
- 510 35. Kelly-Arnold A, Maldonado N, Laudier D, Aikawa E, Cardoso L, Weinbaum S. Revised
- 511 microcalcification hypothesis for fibrous cap rupture in human coronary arteries. *Proc*512 *Natl Acad Sci U S A*. 2013;110:10741–10746.
- 513 36. Doradla P, Otsuka K, Nadkarni A, Villiger M, Karanasos A, Zandvoort LJC van, Dijkstra
- 514 J, Zijlstra F, Soest G van, Daemen J, Regar E, Bouma BE, Nadkarni SK. Biomechanical
- 515 Stress Profiling of Coronary Atherosclerosis: Identifying a Multifactorial Metric to
- 516 Evaluate Plaque Rupture Risk. *JACC Cardiovasc Imaging*. 2020;13:804–816.
- 517 37. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. *Nat Rev Cardiol*.
  518 2022;19:593–606.
- 519 38. Hwang I-C, Park HE, Choi S-Y. Epicardial Adipose Tissue Contributes to the
- 520 Development of Non-Calcified Coronary Plaque: A 5-Year Computed Tomography
- 521 Follow-up Study. *J Atheroscler Thromb*. 2017;24:262–274.

522	39.	Mancio J, Azevedo D, Saraiva F, Azevedo AI, Pires-Morais G, Leite-Moreira A, Falcao-
523		Pires I, Lunet N, Bettencourt N. Epicardial adipose tissue volume assessed by computed
524		tomography and coronary artery disease: a systematic review and meta-analysis. Eur
525		Hear journal Cardiovasc Imaging. 2018;19:490–497.
526	40.	Madonna R, Massaro M, Scoditti E, Pescetelli I, De Caterina R. The epicardial adipose
527		tissue and the coronary arteries: Dangerous liaisons. Cardiovasc Res. 2019;115:1013-
528		1025.
529	41.	Antonopoulos AS, Sanna F, Sabharwal N, Thomas S, Oikonomou EK, Herdman L,
530		Margaritis M, Shirodaria C, Kampoli A-M, Akoumianakis I, Petrou M, Sayeed R,
531		Krasopoulos G, Psarros C, Ciccone P, Brophy CM, Digby J, Kelion A, Uberoi R, Anthony
532		S, Alexopoulos N, Tousoulis D, Achenbach S, Neubauer S, Channon KM, Antoniades C.
533		Detecting human coronary inflammation by imaging perivascular fat. Sci Transl Med.
534		2017;9. doi:10.1126/scitranslmed.aal2658.
535	42.	Oikonomou EK, Marwan M, Desai MY, Mancio J, Alashi A, Hutt Centeno E, Thomas S,
536		Herdman L, Kotanidis CP, Thomas KE, Griffin BP, Flamm SD, Antonopoulos AS,
537		Shirodaria C, Sabharwal N, Deanfield J, Neubauer S, Hopewell JC, Channon KM,
538		Achenbach S, Antoniades C. Non-invasive detection of coronary inflammation using
539		computed tomography and prediction of residual cardiovascular risk (the CRISP CT
540		study): a post-hoc analysis of prospective outcome data. Lancet (London, England).
541		2018;392:929–939.
542	43.	Del Buono MG, Montone RA, Camilli M, Carbone S, Narula J, Lavie CJ, Niccoli G, Crea
543		F. Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases:
544		JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;78:1352–1371.

545	44.	Kelshiker MA, Seligman H, Howard JP, Rahman H, Foley M, Nowbar AN, Rajkumar CA,
546		Shun-Shin MJ, Ahmad Y, Sen S, Al-Lamee R, Petraco R. Coronary flow reserve and
547		cardiovascular outcomes: a systematic review and meta-analysis. Eur Heart J.
548		2022;43:1582–1593.
549	45.	Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart
550		JC, James WPT, Loria CM, Smith SC. Harmonizing the metabolic syndrome: A joint
551		interim statement of the international diabetes federation task force on epidemiology and
552		prevention; National heart, lung, and blood institute; American heart association; World
553		heart federation; International . Circulation. 2009;120:1640-1645.
554	46.	Nishimoto S, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Murata C, Kim-Kaneyama
555		J-R, Sato F, Bando M, Yagi S, Soeki T, Hayashi T, Imoto I, Sakaue H, Shimabukuro M,
556		Sata M. Obesity-induced DNA released from adipocytes stimulates chronic adipose tissue
557		inflammation and insulin resistance. Sci Adv. 2016;2:e1501332.

# 559 Tables

	Non-MetS		Me	P value	
-	DM (-)	DM (+)	DM (-)	DM (+)	
	(n = 306)	(n = 52)	(n = 114)	(n = 58)	
Age	64 (15)	69 (10)	62 (13)	66 (12)	< 0.001
Male, n (%)	158 (52%)	32 (62%)	70 (61%)	39 (67%)	0.062
BMI, kg/mm <sup>2</sup>	22.7 (3.4)	22.1 (2.8)	26.6 (4.2)	27.7 (4.6)	< 0.001
VAT area, cm <sup>2</sup>	78 (41)	66 (32)	148 (45)	168 (62)	< 0.001
Subcutaneous fat area, cm <sup>2</sup>	137 (70)	105 (67)	200 (98)	192 (82)	< 0.001
Systolic BP, mmHg	136 (21)	145 (22)	148 (24)	148 (25)	< 0.001
Diastolic BP, mmHg	76 (13)	79 (17)	84 (14)	81 (13)	< 0.001
Triglyceride, mg/dL	134 (141)	125 (98)	221 (244)	241 (488)	0.001
HDL-C, mg/dL	67 (19)	65 (17)	56 (15)	50 (13)	< 0.001
LDL-C, mg/dL	124 (33)	110 (38)	135 (36)	115 (32)	< 0.001
Fasting plasma glucose, g/dL	105 (18)	178 (86)	113 (21)	157 (58)	< 0.001

Table 1. Patient characteristics according to metabolic phenotypes

Hemoglobin A1c, %	5.6 (0.3)	7.1 (1.7)	5.7 (0.3)	7.2 (1.8)	< 0.001
CRP (LogCRP)	0.31 (0.86)	0.20 (0.34)	0.31 (0.71)	0.35 (0.49)	< 0.001
TyG index	8.6 (0.56)	9.0 (0.81)	9.1 (0.66)	9.4 (0.79)	< 0.001
Hypertension	168 (55%)	44 (85%)	107 (94%)	54 (93%)	< 0.001
Diabetes mellitus	0 (0%)	52 (100%)	0 (%)	58 (100%)	-
Dyslipidemia	155 (51%)	36 (69%)	113 (99%)	49 (84%)	< 0.001
Current or former tobacco	38 (12%)	10 (19%)	21 (18%)	10 (17%)	0.306
use					
CKD	72 (24%)	14 (27%)	29 (25%)	16 (28%)	0.883
Suita CVD risk score	23.5 (10.8)	35.5 (9.3)	26.0 (9.0)	33.9 (9.0)	< 0.001
Atrial fibrillation	27 (8.8%)	10 (19%)	9 (7.8%)	9 (16%)	0.056
Medications					
ACE inhibitor or ARB	47 (15%)	15 (29%)	34 (30%)	21 (36%)	< 0.001
Calcium channel blocker	61 (20%)	18 (35%)	39 (34%)	21 (36%)	0.002
β-blocker	11 (3.5%)	5 (9.6%)	10 (8.8%)	4 (6.8%)	0.102
Statins	39 (13%)	18 (35%)	42 (37%)	23 (40%)	< 0.001

- 561 Values are given as mean  $\pm$  standard deviation or number (%).
- 562 ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; BP, blood pressure; CKD,
- 563 chronic kidney disease; CRP, C-reactive protein; CVD, cardiovascular disease; TyG, triglyceride-glucose; VAT, visceral adipose
- 564 tissue; HDL, high-density lipoprotein; LDL, low-density lipoprotein; DM (-), without diabetes mellitus; DM (+), with diabetes
- 565 mellitus; MetS: metabolic syndrome
- 566

Table 2. Co	CTA findings	s according to	metabolic <sub>1</sub>	ohenotypes

	Non-N	Non-MetS		MetS		
	DM (-)	DM (+)	DM (-)	DM (+)		
	(n = 306)	(n = 52)	(n = 114)	(n = 58)		
CACS						
CACS 0	153 (50%)	13 (25%)	49 (43%)	14 (24%)	< 0.001	
CACS 1-100	77 (25%)	13 (25%)	36 (32%)	14 (24%)	0.569	
CACS 101-400	54 (18%)	15 (29%)	19 (17%)	17 (29%)	0.056	
CACS >400	22 (7.2%)	11 (21%)	10 (8.8%)	13 (22%)	< 0.001	
Stenosis severity on CCTA	L					

No CAD	64 (21 %)	5 (9.6%)	19 (17%)	5 (8.6%)	0.048
Non-obstructive CAD	131 (43 %)	17 (33%)	51 (45%)	26 (45%)	0.490
Obstructive CAD	111 (36 %)	30 (58%)	44 (39%)	27 (46%)	0.021
Coronary plaque burden					
NCP volume, %	19.7 (5.7)	20.6 (6.6)	21.2 (6.9)	23.4 (8.4)	< 0.001
LAP volume, %	2.4 (1.7)	3.2 (2.6)	3.3 (2.9)	4.4 (5.0)	0.001
CP volume, %	0.7 (2.4)	2.1 (3.9)	0.9 (2.9)	1.6 (3.7)	0.002
EAT volume, ml	105 (42)	107 (40)	148 (46)	176 (46)	< 0.001
EAT mean CT value, HU	-79.0 (5.3)	-77.7 (5.3)	-80.7 (4.0)	-79.5 (5.0)	0.001

567 Values are given as mean  $\pm$  standard deviation or number (%).

568 CACS, coronary artery calcium score; CAD, coronary artery disease; CP, calcified plaque; DM (-), without diabetes mellitus; DM (+),

569 with diabetes mellitus; EAT, epicardial adipose tissue; MetS, metabolic syndrome; NCP, non-calcified plaque; LAP, low-attenuation

570 plaque; CCTA, coronary computed tomography angiography; CT, computed tomography; HU, Hounsfield unit

	Non-	95% CI	Р	Non-adjusted	95% CI	Р	Non-adjusted HR	95% CI	Р
	adjusted			HR					
	HR								
	All patients	s (n = 530)		Women (n = 231)			Men (n = 299)		
Age	1.03	1.002-1.070	0.040	1.05	0.98–1.12	0.147	1.03	0.99–1.07	0.085
Male	1.65	0.72-3.88	0.229						
CACS >400	5.09	2.25–11.54	< 0.001	8.96	2.14-37.5	0.003	3.68	1.36–9.97	0.010
LAP volume	6.03	2.70-13.4	< 0.001	17.5	3.54-87.2	< 0.001	3.52	1.36—9.14	0.009
> 4%									
Obstructive	8.45	2.90-24.60	< 0.001	13.2	1.63–107.7	0.016	6.51	1.87–22.6	0.003
CAD									
Obstructive	4.40	2.16-8.99	< 0.001	3.90	1.31-11.6	0.014	1.98	0.91-4.29	0.082
CAD in LAD									
Obstructive	2.47	1.10-5.54	0.027	1.53	0.341-6.94	0.575	2.70	1.20-6.09	0.016
CAD in LCX									
Obstructive	3.13	1.43-6.82	0.004	4.05	1.23-13.3	0.021	3.05	1.35-6.88	0.007

# Table 3. Unadjusted Cox proportional hazards model to predict the primary outcome

	•	D	$\sim$
1 · A I A	1 10		( <u>`</u> A
1 AIJ		- <b>R</b> 1	I AI
$\mathcal{O}_{I}\mathcal{I}\mathcal{D}$	111	- 1.	$\nabla I$

EAT volume	1.001	0.993-1.008	0.853	1.01	0.99–1.02	0.138	0.99	0.98–1.005	0.374
EAT mean	1.03	0.99–1.083	0.126	1.02	0.95–1.10	0.442	1.06	0.96–1.18	0.222
CT vale									
BMI	0.45	0.16–1.20	0.111	0.02	0.000-13.16	0.252	0.68	0.24–1.94	0.477
$\geq 25 \text{kg/m}^2$									
VAT ≥100	1.28	0.58–2.80	0.535	1.18	0.28-4.96	0.815	1.16	0.44–3.06	0.761
cm <sup>2</sup>									
MetS	1.39	0.627–3.10	0.415	1.62	0.38–6.80	0.506	1.23	0.46-3.23	0.673
DM	3.74	1.70-8.20	0.001	5.22	1.30-20.9	0.019	3.02	1.16–7.83	0.023
Chronic	1.64	0.800-3.39	0.175	1.30	0.403-4.248	0.655	1.89	0.86-4.18	0.113
kidney									
disease									
CRP	1.25	0.70-2.23	0.449	1.34	0.54-3.29	0.522	1.39	0.77-2.52	0.273
TyG index	1.80	1.24-2.62	0.002	2.29	0.89-5.89	0.084	1.34	0.86-2.07	0.192

BMI, body mass index; CACS, coronary artery calcium score; CAD, coronary artery disease; EAT, epicardial adipose tissue; VAT, visceral adipose tissue;

HDL, high-density lipoprotein; LDL, low-density lipoprotein; DM, diabetes mellitus; MetS: metabolic syndrome

CRP was log transformed for analysis.

	Predictor	Hazard	95% confidence interval	P value
		ratio		
Model 1	DM	2.68	1.16-6.18	0.02
	(Reference, non-DM)			
	Low-attenuation plaque volume > 4%	5.41	2.42–12.11	< 0.001
Model 2	MetS	0.99	0.44–2.23	0.99
	(Reference, non-MetS)			
	Low-attenuation plaque volume > 4%	5.83	2.59–13.10	< 0.001
Model 3	DM without MetS	6.89	2.33–20.39	0.001
	(Reference, non-DM without MetS)			
	Low-attenuation plaque volume > 4%	9.66	3.29–28.35	< 0.001
Model 4	DM with MetS	1.69	0.56–5.09	0.34
	(Reference, non-DM without MetS)			
	Low-attenuation plaque volume > 4%	9.24	2.82-30.27	< 0.001

 Table 4. Cox proportional hazards analysis to predict major cardiovascular adverse events

	Model 5	Non-DM without MetS	2.24	0.58-8.53	0.23
		(Reference, non-DM without MetS)			
		Low-attenuation plaque volume > 4%	4.62	1.37–15.51	0.013
	Models 1-	5 were adjusted by Suita CVD risk score. D	M, diabetes melli	itus; MetS, Metabolic syndro	me
574					
575					
576					
577					
578					
579					
580					
581					
582					
583					
584					
585					
586					

# 587 Figure Legends

# 588 Figure 1. Flow chart of study patients

- 589 A flowchart depicting the 530 patients who underwent CCTA examination and how they were divided into No-MetS and MetS groups.
- 590 Patients were further categorized into four groups according to the presence or absence of metabolic equivalents (MetS) and DM.
- 591 CCTA, coronary computed tomography angiography; DM, diabetes mellitus; MetS, metabolic syndrome.
- 592

# 593 Figure 2. Kaplan–Meier analysis for prediction of MACE stratified by metabolic phenotypes

594 Kaplan-Meier curves demonstrating significant differences between metabolic phenotypes in cumulative event rates, using a

595 composite endpoint of cardiovascular death, acute coronary syndrome, and symptom- or ischemia-driven coronary revascularization.

- 596 Higher event rates were present in non-MetS patients with DM (log-rank test, p < 0.001), followed by MetS with DM (log-rank test, p
- 597 <0.001). DM, diabetes mellitus; MetS, metabolic syndrome; MACE, major adverse cardiovascular event.



